Had/have the following prior/concurrent therapy: 
Systemic corticosteroids (oral or injectable) within 7 days of first dose of 852A (topical or inhaled steroids are allowed) 
Investigational drugs/agents within 14 days of first dose of 852A 
Immunosuppressive therapy, including cytotoxic agents within 14 days of first dose of 852A (nitrosoureas within 30 days of first dose) 
Drugs known to induce QT interval prolongation and/or induce Torsades de pointes unless best available drug required to treat life-threatening conditions 
Radiotherapy within 3 weeks of the first dose of 852A 
Hematopoietic cell transplantation within 4 weeks of first dose of 852A 
Evidence of active infection within 3 days of first dose of 852A 
Active fungal infection or pulmonary infiltrates (prior treated disease stable for 2 weeks is allowable) 
Cardiac ischemia, cardiac arrhythmias or congestive heart failure uncontrolled by medication 
History of, or clinical evidence of, a condition which, in the opinion of the investigator, could confound the results of the study or put the subject at undue risk 
Uncontrolled intercurrent or chronic illness 
Active autoimmune disease requiring immunosuppressive therapy within 30 days 
Active coagulation disorder not controlled with medication 
Pregnant or lactating 
Concurrent malignancy (if in remission, at least 5 years disease free) except for localized (in-situ) disease, basal carcinomas and cutaneous squamous cell carcinomas that have been adequately treated 
Any history of brain metastases or any other active central nervous system (CNS) disease       
    

NCT00319748_exc_T1
Drug
Systemic corticosteroids
NCT00319748_exc_T2
Temporal
within 7 days of first dose
NCT00319748_exc_T3
Drug
852A
NCT00319748_exc_T4
Drug
topical steroids
NCT00319748_exc_T5
Drug
inhaled steroids
NCT00319748_exc_T6
Scope
topical or inhaled steroids are allowed
NCT00319748_exc_T7
Drug
Investigational drugs/agents
NCT00319748_exc_T8
Temporal
within 14 days of first dose
NCT00319748_exc_T9
Drug
852A
NCT00319748_exc_T10
Procedure
Immunosuppressive therapy
NCT00319748_exc_T11
Drug
cytotoxic agents
NCT00319748_exc_T12
Temporal
within 14 days of first dose
NCT00319748_exc_T13
Drug
852A
NCT00319748_exc_T14
Drug
nitrosoureas
NCT00319748_exc_T15
Temporal
within 30 days of first dose
NCT00319748_exc_T16
Drug
Drugs known to induce QT interval prolongation
NCT00319748_exc_T17
Drug
Drugs known to induce Torsades de pointes
NCT00319748_exc_T19
Scope
Drugs known to induce QT interval prolongation and/or induce Torsades de pointes
NCT00319748_exc_T20
Procedure
Radiotherapy
NCT00319748_exc_T21
Temporal
within 3 weeks of the first dose
NCT00319748_exc_T22
Drug
852A
NCT00319748_exc_T23
Procedure
Hematopoietic cell transplantation
NCT00319748_exc_T24
Temporal
within 4 weeks of first dose
NCT00319748_exc_T25
Drug
852A
NCT00319748_exc_T26
Condition
active infection
NCT00319748_exc_T27
Observation
Evidence
NCT00319748_exc_T28
Temporal
within 3 days of first dose
NCT00319748_exc_T29
Drug
852A
NCT00319748_exc_T30
Condition
fungal infection
NCT00319748_exc_T31
Condition
pulmonary infiltrates
NCT00319748_exc_T32
Condition
prior treated disease
NCT00319748_exc_T33
Qualifier
stable
NCT00319748_exc_T34
Temporal
for 2 weeks
NCT00319748_exc_T35
Scope
fungal infection or pulmonary infiltrates
NCT00319748_exc_T36
Condition
Cardiac ischemia
NCT00319748_exc_T37
Condition
cardiac arrhythmias
NCT00319748_exc_T38
Condition
congestive heart failure
NCT00319748_exc_T39
Qualifier
uncontrolled by medication
NCT00319748_exc_T40
Observation
History
NCT00319748_exc_T41
Observation
clinical evidence
NCT00319748_exc_T42
Condition
could confound the results of the study or put the subject at undue risk a condition which
NCT00319748_exc_T43
Scope
History of, or clinical evidence of
NCT00319748_exc_T44
Condition
intercurrent illness
NCT00319748_exc_T45
Condition
chronic illness
NCT00319748_exc_T46
Qualifier
Uncontrolled
NCT00319748_exc_T47
Condition
autoimmune disease
NCT00319748_exc_T48
Qualifier
requiring
NCT00319748_exc_T49
Procedure
immunosuppressive therapy
NCT00319748_exc_T50
Temporal
within 30 days
NCT00319748_exc_T51
Condition
coagulation disorder
NCT00319748_exc_T52
Temporal
Active
NCT00319748_exc_T53
Temporal
Active
NCT00319748_exc_T54
Qualifier
controlled with medication
NCT00319748_exc_T55
Negation
not
NCT00319748_exc_T56
Condition
Pregnant
NCT00319748_exc_T57
Condition
lactating
NCT00319748_exc_T58
Condition
malignancy
NCT00319748_exc_T59
Temporal
Concurrent
NCT00319748_exc_T60
Value
at least 5 years
NCT00319748_exc_T61
Qualifier
disease free
NCT00319748_exc_T62
Qualifier
in remission
NCT00319748_exc_T63
Condition
localized (in-situ) disease
NCT00319748_exc_T64
Condition
basal carcinomas
NCT00319748_exc_T65
Condition
cutaneous squamous cell carcinomas
NCT00319748_exc_T66
Qualifier
adequately treated
NCT00319748_exc_T67
Scope
localized (in-situ) disease, basal carcinomas and cutaneous squamous cell carcinomas
NCT00319748_exc_T68
Condition
brain metastases
NCT00319748_exc_T69
Observation
history of
NCT00319748_exc_T70
Condition
any other central nervous system (CNS) disease
NCT00319748_exc_T71
Temporal
active
NCT00319748_exc_T72
Scope
brain metastases or any other active central nervous system (CNS) disease
NCT00319748_exc_T73
Negation
is allowable
NCT00319748_exc_T74
Scope
prior treated disease stable for 2 weeks is allowable
NCT00319748_exc_T75
Negation
except for
NCT00319748_exc_T76
Scope
localized (in-situ) disease, basal carcinomas and cutaneous squamous cell carcinomas that have been adequately treated
NCT00319748_exc_T77
Negation
are allowed
NCT00319748_exc_T78
Scope
topical or inhaled steroids
NCT00319748_exc_T83
Qualifier
injectable
NCT00319748_exc_T84
Qualifier
oral
NCT00319748_exc_T85
Scope
oral or injectable